Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

V3640

Sigma-Aldrich

Valpromide

≥97% (NMR)

Sinonimo/i:

2-Propylvaleramide, 2-propyl-pentanamide, Depamid, Depamide, Di-n-propylacetamide, Dipropylacetamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C8H17NO
Numero CAS:
Peso molecolare:
143.23
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

Livello qualitativo

Saggio

≥97% (NMR)

Forma fisica

powder

Colore

white to off-white

Solubilità

DMSO: >10 mg/mL

Ideatore

Sanofi Aventis

Temperatura di conservazione

room temp

Stringa SMILE

CCCC(CCC)C(N)=O

InChI

1S/C8H17NO/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H2,9,10)
OMOMUFTZPTXCHP-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Valpromide has been used to pretreat NIH/3T3 cells to test its effect on cytomegalovirus (CMV) viral replication. It has also been used to test its antiviral functionality in herpes simplex virus type 1 (HSV-1) infected human oligodendroglioma (HOG) cells. It may be used to test its effect on apoptosis induction in astrocytes.

Azioni biochim/fisiol

Valpromide (VPD) is a derivative of valproic acid (VPA) and is used as an antiepileptic drug. It is hydrolyzed quickly to VPA in vivo, but has intrinsic anticonvulsant activity.
Valpromide possesses antipsychotic property. It lacks the toxic and teratogenic effects of valproic acid. It also lacks the histone deacetylase (HDAC) inhibitory activity of valproic acid.

Caratteristiche e vantaggi

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Exclamation mark

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Octanoic acid analytical standard

Supelco

21639

Octanoic acid

Sodium valproate European Pharmacopoeia (EP) Reference Standard

S0930000

Sodium valproate

Hydrobenzoin

Sigma-Aldrich

301426

Hydrobenzoin

Betaine ≥98% (perchloric acid titration)

Sigma-Aldrich

B2629

Betaine

Galit Shaltiel et al.
Biological psychiatry, 56(11), 868-874 (2004-12-04)
Lithium and valproate (VPA) are used for treating bipolar disorder. The mechanism of mood stabilization has not been elucidated, but the role of inositol has gained substantial support. Lithium inhibition of inositol monophosphatase, an enzyme required for inositol recycling and
Joseph R Calabrese et al.
Bipolar disorders, 9(6), 628-635 (2007-09-12)
Agomelatine has been shown to be safe and efficient in the treatment of major depressive disorder at 25 mg daily. The aim of this study was to gather preliminary data regarding the antidepressant efficacy of agomelatine in patients with bipolar
M Bialer
Clinical pharmacokinetics, 20(2), 114-122 (1991-02-01)
Valpromide has been used as an antiepileptic and antipsychotic drug for the past 25 years in several European countries. Unlike its corresponding acid, valproic acid, whose pharmacokinetics have been quite extensively reviewed, and despite years of clinical use, it appears
Valproic acid induces apoptosis in differentiating hippocampal neurons by the release of tumor necrosis factor-alpha from activated astrocytes
Wang C, et al.
Neuroscience Letters, 497(2), 122-127 (2011)
Karine Cambon et al.
Molecular therapy. Methods & clinical development, 5, 259-276 (2017-06-13)
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder resulting from a polyglutamine expansion in the huntingtin (HTT) protein. There is currently no cure for this disease, but recent studies suggest that RNAi to downregulate the expression of both normal

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.